| HUMAN-TRIAL | evidence | Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide | Liver health · n = 51 | — |
| HUMAN-TRIAL | evidence | GLP-1R Agonist Treatment for Opioid Use Disorder | Ozempic | Addiction & substance use · human-rct · n = 200 | — |
| HUMAN-TRIAL | evidence | Semaglutide Therapy for Alcohol Reduction (STAR) | Semaglutide | Addiction & substance use · human-rct · n = 63 | — |
| HUMAN-TRIAL | evidence | Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? | Wegovy | Addiction & substance use · human-rct · n = 108 | — |
| HUMAN-TRIAL | evidence | Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Semaglutide | Weight & fat loss · human-rct · n = 407 | — |
| HUMAN-TRIAL | evidence | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | Wegovy | Weight & fat loss · human-rct · n = 168 | — |
| HUMAN-TRIAL | evidence | Lifestyle Counseling and Medication for Adolescent Weight Management | Semaglutide | Weight & fat loss · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People | Semaglutide | Glycemic control · human-rct · n = 16 | — |
| HUMAN-TRIAL | evidence | Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 | Ozempic | human-rct · n = 400 | — |
| HUMAN-TRIAL | evidence | A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Wegovy | Weight & fat loss · human-rct · n = 64 | — |
| HUMAN-TRIAL | evidence | Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity | Ozempic | Weight & fat loss · human-observational · n = 154 | — |
| HUMAN-TRIAL | evidence | The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | Semaglutide | Glycemic control · human-rct · n = 50 | — |
| HUMAN-TRIAL | evidence | Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Semaglutide | Weight & fat loss · human-rct · n = 611 | — |
| HUMAN-TRIAL | evidence | Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes | Semaglutide | Glycemic control · human-observational · n = 400 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction | Semaglutide | human-observational · n = 26000 | — |
| HUMAN-TRIAL | evidence | Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Semaglutide | Weight & fat loss · human-rct · n = 307 | — |
| HUMAN-TRIAL | evidence | The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | Ozempic | human-rct · n = 20 | — |
| HUMAN-TRIAL | evidence | Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Semaglutide | human-rct · n = 270 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 187 | — |
| HUMAN-TRIAL | evidence | Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. | Semaglutide | Weight & fat loss · human-rct · n = 62 | — |
| HUMAN-TRIAL | evidence | Semaglutide Treatment for Hyperglycaemia After Renal Transplantation | Rybelsus | Glycemic control · human-rct · n = 104 | — |
| HUMAN-TRIAL | evidence | A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | Semaglutide | Weight & fat loss · human-rct · n = 29 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Semaglutide | Glycemic control · n = 148 | — |
| HUMAN-TRIAL | evidence | A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | Semaglutide | Weight & fat loss · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-observational · n = 43 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 300 | — |
| HUMAN-TRIAL | evidence | Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Semaglutide | Weight & fat loss · human-rct · n = 98 | — |
| HUMAN-TRIAL | evidence | STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Semaglutide | Weight & fat loss · n = 500 | — |
| HUMAN-TRIAL | evidence | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Semaglutide | Glycemic control · human-rct · n = 504 | — |
| HUMAN-TRIAL | evidence | A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India | Semaglutide | Glycemic control · human-observational · n = 388 | — |
| HUMAN-TRIAL | evidence | Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects | Semaglutide | Glycemic control · human-rct · n = 78 | — |
| HUMAN-TRIAL | evidence | A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 15 | — |
| HUMAN-TRIAL | evidence | Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | Semaglutide | Weight & fat loss · human-rct · n = 20 | — |
| HUMAN-TRIAL | evidence | A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide | Weight & fat loss · human-rct · n = 201 | — |
| HUMAN-TRIAL | evidence | Effect of Semaglutide in Patients With Psoriasis and Obesity | Semaglutide | Weight & fat loss · n = 14 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Wegovy | Weight & fat loss · human-rct · n = 500 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 813 | — |
| HUMAN-TRIAL | evidence | BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 374 | — |
| HUMAN-TRIAL | evidence | Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment | Semaglutide | human-rct · n = 54 | — |
| HUMAN-TRIAL | evidence | A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice | Wegovy | Weight & fat loss · human-observational · n = 1250 | — |
| HUMAN-TRIAL | evidence | Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Semaglutide | Weight & fat loss · human-rct · n = 207 | — |
| HUMAN-TRIAL | evidence | Preoperative Semaglutide Prior to Radical Prostatectomy | Semaglutide | n = 20 | — |
| HUMAN-TRIAL | evidence | A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 87 | — |
| HUMAN-TRIAL | evidence | Exercise and GLP-1 RA on Insulin Secretion | Semaglutide | Glycemic control · human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study | Semaglutide | Weight & fat loss · human-observational · n = 190 | — |
| HUMAN-TRIAL | evidence | Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant | Wegovy | human-rct · n = 50 | — |
| HUMAN-TRIAL | evidence | Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | Ozempic | Glycemic control · human-rct · n = 252 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Semaglutide | Glycemic control · human-rct · n = 731 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction | Semaglutide | Glycemic control · human-observational · n = 28118 | — |
| HUMAN-TRIAL | evidence | Incretin Microdosing for Cardiometabolic Health in People With HIV | Semaglutide | human-rct · n = 30 | — |